Market Research Logo

Heptares Therapeutics Ltd. - Product Pipeline Review - 2015

Heptares Therapeutics Ltd. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Heptares Therapeutics Ltd. - Product Pipeline Review - 2015’, provides an overview of the Heptares Therapeutics Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Heptares Therapeutics Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Heptares Therapeutics Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Heptares Therapeutics Ltd.’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Heptares Therapeutics Ltd.’s pipeline products
Reasons to buy
  • Evaluate Heptares Therapeutics Ltd.’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Heptares Therapeutics Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Heptares Therapeutics Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Heptares Therapeutics Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Heptares Therapeutics Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Heptares Therapeutics Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


Heptares Therapeutics Ltd. Snapshot
Heptares Therapeutics Ltd. Overview
Key Information
Key Facts
Heptares Therapeutics Ltd. - Research and Development Overview
Key Therapeutic Areas
Heptares Therapeutics Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
Heptares Therapeutics Ltd. - Pipeline Products Glance
Heptares Therapeutics Ltd. - Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Heptares Therapeutics Ltd. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Heptares Therapeutics Ltd. - Drug Profiles
HTL-9936
Product Description
Mechanism of Action
R&D Progress
Drug to Agonize Muscarinic M1/M4 Receptors for Psychosis and Cognitive Impairment
Product Description
Mechanism of Action
R&D Progress
Drug to Agonize Muscarinic M4 Receptors for Psychosis
Product Description
Mechanism of Action
R&D Progress
HTL-14242
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize GLP-1 Receptor for Type 2 Diabetes
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Agonize GPR-39 for Type 2 Diabetes
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize CGRP for Migraine
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Target GPCR for Pain, Metabolic Disorders and Inflammation
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Addiction and Compulsive Disorders
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Antagonize Orexin 1/2 for Insomnia
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target Chemokine (C-X-C Motif) Receptor 4 for Cancer and HIV
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target GPCR for CNS Disorders
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Target mGluR2 for Schizophrenia
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Target GPCR
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Target GPCRs for Pain, Metabolic Disorders and Inflammation
Product Description
Mechanism of Action
R&D Progress
Heptares Therapeutics Ltd. - Pipeline Analysis
Heptares Therapeutics Ltd. - Pipeline Products by Target
Heptares Therapeutics Ltd. - Pipeline Products by Route of Administration
Heptares Therapeutics Ltd. - Pipeline Products by Molecule Type
Heptares Therapeutics Ltd. - Pipeline Products by Mechanism of Action
Heptares Therapeutics Ltd. - Recent Pipeline Updates
Heptares Therapeutics Ltd. - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Heptares Therapeutics Ltd., Key Information
Heptares Therapeutics Ltd., Key Facts
Heptares Therapeutics Ltd. - Pipeline by Indication, 2015
Heptares Therapeutics Ltd. - Pipeline by Stage of Development, 2015
Heptares Therapeutics Ltd. - Monotherapy Products in Pipeline, 2015
Heptares Therapeutics Ltd. - Partnered Products in Pipeline, 2015
Heptares Therapeutics Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
Heptares Therapeutics Ltd. - Out-Licensed Products in Pipeline, 2015
Heptares Therapeutics Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
Heptares Therapeutics Ltd. - Phase I, 2015
Heptares Therapeutics Ltd. - Preclinical, 2015
Heptares Therapeutics Ltd. - Discovery, 2015
Heptares Therapeutics Ltd. - Pipeline by Target, 2015
Heptares Therapeutics Ltd. - Pipeline by Route of Administration, 2015
Heptares Therapeutics Ltd. - Pipeline by Molecule Type, 2015
Heptares Therapeutics Ltd. - Pipeline Products by Mechanism of Action, 2015
Heptares Therapeutics Ltd. - Recent Pipeline Updates, 2015
List of Figures
Heptares Therapeutics Ltd. - Pipeline by Top 10 Indication, 2015
Heptares Therapeutics Ltd. - Pipeline by Stage of Development, 2015
Heptares Therapeutics Ltd. - Monotherapy Products in Pipeline, 2015
Heptares Therapeutics Ltd. - Out-Licensed Products in Pipeline, 2015
Heptares Therapeutics Ltd. - Pipeline by Top 10 Target, 2015
Heptares Therapeutics Ltd. - Pipeline by Top 10 Route of Administration, 2015
Heptares Therapeutics Ltd. - Pipeline by Top 10 Molecule Type, 2015
Heptares Therapeutics Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report